Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Genome-wide Association Studies-GWAS

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Cancers Originate from Somatic Mutations in a Single Cell

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Clinical validation of an HPV whole-genome sequencing assay for MRD detection in patients with HPV+ head and neck cancer treated with surgery.

Science translational medicine·2026

Same author

Homologous recombination deficiency and hemizygosity drive resistance in breast cancer.

Nature·2026

Same author

Association of Circulating T Cell and Tumor Microenvironment Profiles with Immune Checkpoint Blockade Outcomes in Sarcoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma.

Cancer research communications·2025

Same author

Tumor miRNA Signatures Associate with Outcomes of Patients with Stage II/III Melanoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025

Same author

Meta-analysis reveals differences in somatic alterations by genetic ancestry across common cancers.

Nature genetics·2025

Same journal

Comprehensive Profiling of Cell Surface Proteins in Testicular Germ Cell Tumors.

Cancer research communications·2026

Same journal

Tissue context shapes distinct premalignant outcomes in a HPV16 E6/E7-mutant Pik3ca transgenic mouse model.

Cancer research communications·2026

Same journal

Association of Cumulative Proton Pump Inhibitor Use with Prostate Cancer Risk and Outcomes: A Population-Based Cohort Study.

Cancer research communications·2026

Same journal

A phase 1b study of chemo-immunotherapy with pegylated liposomal doxorubicin and Pembrolizumab in estrogen receptor positive metastatic breast cancer.

Cancer research communications·2026

Same journal

DNA Methyltransferase Inhibition Prevents Platinum-Induced Ovarian Cancer Stem Cell Enrichment.

Cancer research communications·2026

Same journal

Chemotherapy Induced Neutropenia in Palestinian Patients with Solid Malignancies: Patient Characteristics, Severity Risk Factors & Management Patterns.

Cancer research communications·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Aug 5, 2025

Detection of Rare Genomic Variants from Pooled Sequencing Using SPLINTER

Detection of Rare Genomic Variants from Pooled Sequencing Using SPLINTER

Published on: June 23, 2012

Predicting Cancer Risk from Germline Whole-exome Sequencing Data Using a Novel Context-based Variant Aggregation

Zoe Guan¹, Colin B Begg¹, Ronglai Shen¹

¹Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.

Cancer Research Communications

|March 27, 2023

Summary

This summary is machine-generated.

Aggregating germline variants using genomic contexts did not improve cancer risk prediction models. Further research with whole-genome sequencing may enhance prediction accuracy for rare cancer-associated genetic variants.

More Related Videos

Detecting Somatic Genetic Alterations in Tumor Specimens by Exon Capture and Massively Parallel Sequencing

Detecting Somatic Genetic Alterations in Tumor Specimens by Exon Capture and Massively Parallel Sequencing

Published on: October 18, 2013

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA

Published on: August 21, 2016

Related Experiment Videos

Last Updated: Aug 5, 2025

Detection of Rare Genomic Variants from Pooled Sequencing Using SPLINTER

Detection of Rare Genomic Variants from Pooled Sequencing Using SPLINTER

Published on: June 23, 2012

Detecting Somatic Genetic Alterations in Tumor Specimens by Exon Capture and Massively Parallel Sequencing

Detecting Somatic Genetic Alterations in Tumor Specimens by Exon Capture and Massively Parallel Sequencing

Published on: October 18, 2013

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA

Published on: August 21, 2016

Area of Science:

Genetics
Cancer Etiology
Bioinformatics

Background:

Genomic, nucleotide, and epigenetic contexts of somatic variants inform cancer etiology.
Germline variant contexts show associations with oncogenic pathways, histologic subtypes, and prognosis.

Purpose of the Study:

To determine if aggregating germline variants using meta-features improves cancer risk prediction.
To investigate the role of rare genetic variants in cancer heritability.

Main Methods:

Utilized germline whole-exome sequencing data from the UK Biobank.
Developed cancer risk models for 10 cancer types using known risk variants and meta-features.
Employed novel statistical methods to analyze rare genetic variants.

Main Results:

Meta-features did not improve the prediction accuracy of models based on known risk variants.
The aggregation approach did not increase statistical power for detecting signals from rare variants.

Conclusions:

Aggregating germline variants by genomic, nucleotide, and epigenetic contexts does not currently enhance cancer risk prediction accuracy.
Future studies incorporating whole-genome sequencing data may yield improved prediction gains.